AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
Thomas O’Hare(Howard Hughes Medical Institute), William C. Shakespeare(Ariadne Diagnostics (United States)), Xiaotian Zhu(Ariadne Diagnostics (United States)), Christopher A. Eide(Howard Hughes Medical Institute), Victor M. Rivera(Ariadne Diagnostics (United States)), Frank Wang(Ariadne Diagnostics (United States)), Lauren T. Adrian(Howard Hughes Medical Institute), Tianjun Zhou(Ariadne Diagnostics (United States)), Wei-Sheng Huang(Ariadne Diagnostics (United States)), Qihong Xu(Ariadne Diagnostics (United States)), Chester A. Metcalf(Ariadne Diagnostics (United States)), Jeffrey Tyner(Oregon Health & Science University), Marc Loriaux(Oregon Health & Science University), Amie S. Corbin(Howard Hughes Medical Institute), Scott Wardwell(Ariadne Diagnostics (United States)), Yaoyu Ning(Ariadne Diagnostics (United States)), Jeffrey Keats(Ariadne Diagnostics (United States)), Yihan Wang(Ariadne Diagnostics (United States)), Raji Sundaramoorthi(Ariadne Diagnostics (United States)), Mathew Thomas(Ariadne Diagnostics (United States)), Dong Zhou(Ariadne Diagnostics (United States)), J. T. Snodgrass(Ariadne Diagnostics (United States)), Lois Commodore(Ariadne Diagnostics (United States)), Tomi K. Sawyer(Ariadne Diagnostics (United States)), David C. Dalgarno(Ariadne Diagnostics (United States)), Michael W. Deininger(Oregon Health & Science University), Brian Druker(Howard Hughes Medical Institute), Tim Clackson(Ariadne Diagnostics (United States))
Cited by 1,243Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis